The UK approved a new COVID-19 vaccine that was developed by Oxford University, AstraZeneca on Wednesday and residents could start receiving it as early as Monday, Jan.4. The Phase III efficacy trial was initiated in India in 25,800 volunteers and till date, ~22,500 participants have been vaccinated across the country and the vaccine has been found to be safe as per the data available till date. The Pune-based Serum Institute has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing "Covishield" while Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) to make "Covaxin". SII had applied for a two full-dose regime about 28 days apart.
This assumes significance for this particular vaccine considering the challenges involved in its storage and deployment, which requires an ultra-cold chain as it needs to be stored at temperatures ranging from -60°C to -90°C degrees - which is one of the reasons, along with the vaccine's high price, at $37, why India hasn't shown much enthusiasm for it. Poonawalla said SII risks on stockpiling the vaccine have paid off.
Pfizer "will review all available information on this case and all reports of any confirmed diagnosis following vaccination", the drug maker said in a statement to Reuters.
Zoë Kravitz files for divorce from Karl Glusman: See his cryptic reaction
But he later told me that he was just nervous, ' recalled Zoe to the outlet at the time. "I was at residence, in sweatpants". For the unversed, the duo was first rumoured to be together back in October 2016 and married in June 2019.
The CDC adds, however, that "if two doses of different mRNA COVID-19 vaccine products are inadvertently administered, no additional doses of either product are recommended at this time".
Under the government's plans, second vaccine doses will take place within 12 weeks of the first - rather than the 21 days initially planned - in an effort to maximise coverage and expand the number of people getting the first vaccination.
India's regulator has also received an emergency-use application for the COVID-19 vaccine made by Pfizer with Germany's BioNTech - the first shot to secure regulatory approval in the West.
India has reported more than 10.3 million COVID-19 cases and around 150,000 deaths, though its rate of infection has come down significantly from a mid-September peak. The Central government plans to vaccinate almost 30 crore people in the first phase of drive in the next six to eight months. It has emerged that India has already managed to stockpile 50 million doses of the jabs.